CME

Faculty: Carolyn Lam, MD, PhD Faculty: Stephen J. Greene, MD Using a real-world patient case, Dr. Stephen Greene and Dr. Carolyn Lam explore strategies to optimize care for patients with heart failure with reduced ejection fraction (HFrEF) who remain at elevated risk despite guideline-directed medical therapy (GDMT). The discussion examines the importance of avoiding clinical inertia, addressing p...

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies...

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies...

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies...

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies...

Faculty: Nancy Helou, PhD Faculty: Steven Fishbane, MD Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recogni...

Faculty: Steven Fishbane, MD Faculty: Nancy Helou, PhD Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recogni...

Faculty: Steven Fishbane, MD Faculty: Nancy Helou, PhD Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recogni...

Faculty: Steven Fishbane, MD Faculty: Nancy Helou, PhD Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recogni...

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies...

Faculty: Amer Zeidan, MBBS, MHS Faculty: Ghayas Issa, MD, MS This chapterized expert interview examines six common clinical decision points encountered when incorporating menin inhibitors into the management of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). Faculty discuss evidence-informed approaches to treatment initiation, monitoring strategies, drug-drug interaction management,...

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection a...

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection a...

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection a...

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection a...

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection a...

Faculty: Michael A. Levine, MD, ML, MACE Faculty: Aliya Khan, MD, FRCPC, FACP, FACE, FASBMR In this expert discussion, Drs. Michael Levine and Aliya Khan review emerging evidence in autosomal dominant hypocalcemia type 1 (ADH1), including findings from the CALIBRATE trial presented at ENDO 2026. They discuss how CaSR-targeted therapy with encaleret may address the underlying disease mechanism and...

Faculty: Ticiana Leal, MD This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engager...

Faculty: Ticiana Leal, MD This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engager...

Faculty: Neal Ready, MD, PhD This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell enga...

Faculty: Neal Ready, MD, PhD This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell enga...

Faculty: Sara A. Hurvitz, MD, FACP Faculty: Tiffany Traina, MD, FASCO The role of antibody-drug conjugate (ADC) therapy has been well established in metastatic breast cancer. Recent phase 3 data have provided evidence for expanded indications for early breast cancer and triple-negative breast cancer (TNBC), leading to updates in current treatment guidelines. In this case-based activity, Drs. Tiffa...

Faculty: Maria Fleseriu, MD, FACE Faculty: Beverly MK Biller, MD, FACP Faculty: Mark Gurnell, MD This program is a replay of the live symposium held at ENDO 2026. This program reviews challenges in diagnosis and management of acromegaly, with an emphasis on earlier recognition and informed clinical decision-making. Faculty discuss heterogeneity of disease presentation and key triggers that should...

Faculty: Christophe Le Tourneau, MD, PhD Faculty: Marc Oliva, MD, PhD This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key...

Faculty: Christophe Le Tourneau, MD, PhD Faculty: Marc Oliva, MD, PhD This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key...